Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | SFRP1 | Q8N474 | 6/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.42 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | WNT3 | P56703 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297738 | 1.00 | HDAC8 (0.47) | HDAC8SFRP1NR1H2STSKIT | |
| SCHEMBL25255089 | 0.88 | HDAC8 (0.48) | HDAC8STSKITDPP4KCNH2 | |
| SCHEMBL30488780 | 0.81 | MGLL (0.45) | STSTGFBR1MGLLABHD6 | |
| SCHEMBL25292247 | 0.81 | MGLL (0.45) | STSTGFBR1MGLLABHD6 | |
| SCHEMBL25146288 | 0.79 | HDAC8 (0.43) | HDAC8STSKITDPP4KCNH2 | |
| SCHEMBL30700579 | 0.79 | KIT (0.44) | HDAC8SFRP1STSKITDPP4 | |
| SCHEMBL30898351 | 0.79 | ABHD6 (0.48) | STSTGFBR1MGLLABHD6PKLR | |
| SCHEMBL30410188 | 0.79 | ABHD6 (0.48) | STSTGFBR1MGLLABHD6PKLR | |
| SCHEMBL25145667 | 0.78 | KIT (0.49) | HDAC8STSKIT | |
| SCHEMBL25146054 | 0.78 | MGLL (0.48) | HDAC8STSKITDPP4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098176-A1 | HETEROCYCLIC COMPOUNDS | CBR3, BRIX1, CCNY | HDAC8 2323/4885SFRP1 3701/4885NR1H2 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.